Expert Discusses Navigating Higher Prices of Chemotherapy Drugs Amid Shortage

Commentary
Video

Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.

It is crucial to ensure that patients continue to receive life-saving treatment with chemotherapy drugs, even if it means purchasing agents at higher price points, according to Luciano N. Gordon, MD.

In an interview with CancerNetwork®, Gordon, president and managing physician at Florida Cancer Specialists & Research Institute who sees patients in the state-wide practice's Gainesville Cancer Center, discussed how his institution has absorbed the rising costs of carboplatin, cisplatin, and other chemotherapy drugs that are currently in short supply across the United States.

Gordan indicated that the limited supply of platinum-based agents such as carboplatin and cisplatin poses a financial challenge, stating that previously low prices made it difficult for sellers to warrant manufacturing and sell these drugs. He stated that it is be “reasonable” to accept paying a elevated price if it means increasing access to these treatments for patients with cancer.

Transcript:

We have allowed purchase of some amount of drugs even at a higher price because we thought it was important to keep the patients on treatment with these life-saving drugs. They're the backbone of several chemotherapy regimens, and many of these patients are receiving these treatments to improve cure rates. Essentially, the practice absorbs the cost, and we did invest the cost to the patient. We can do this for awhile but if price increases or gouging is allowed to go unchecked—if a drug costs $1000 or $10,000, if you have price gouging of 200%, 300%, 1000%, or more—then it's impossible to stay in business and to get the drug to the patients.

I think the problem is that with some of these drugs that are in shortage—specifically the platinum agents, carboplatin and cisplatin—it is a financial problem because the price of these drugs got so low that is not feasible for a manufacturer to produce these drugs. I think most of us would be reasonable and be able to pay a slightly higher price than the current [price] to allow improved supplies.

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Related Content